Market Overview:
The global Imbruvica market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of lymphoma, increasing demand for targeted therapies, and growing awareness about Imbruvica. By type, the 5 mg segment is expected to account for the largest share of the global Imbruvica market in 2018. By application, mantle cell lymphoma is expected to account for the largest share of the global Imbruvica market in 2018. North America is expected to dominate the global Imbruvica market in terms of revenue in 2018.
Product Definition:
Imbruvica is a drug used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is a kinase inhibitor that works by blocking the activity of certain enzymes that help cancer cells grow.
5 mg:
The 5-mg/mL concentration of brolucizumab is a fully human monoclonal antibody that binds to the CD22 antigen on the B-cell surface. It is approved in Europe and Japan for patients with relapsed or refractory chronic lymphatic leukemia (CLL). The U.S.
10 mg:
Imbruvica (brimstone) is a chemotherapy drug and has been used in the treatment of advanced prostate cancer. It works by destroying the cancer cells. The dosage for men is 10 mg/day, which is administered intravenously every three to four days as a single dose or in divided doses throughout the treatment course.
U.S Prostate Cancer Drug Market Size Analysis Report By Product (Brimstone), 2014 - 2020 -> The U.
Application Insights:
Chronic lymphocytic leukemia (CLL) accounted for the largest share of 24.3% in 2017 owing to its high prevalence and wide treatment window. The introduction of Imbruvica tablets 5 mg & 10 mg as a first line therapy is expected to boost the segment growth over the forecast period. Moreover, increasing awareness about CLL due to increasing geriatric population is anticipated to further drive this segment over the forecast period.
The mantle cell lymphoma segment held a significant share in 2017 and is expected to grow at a lucrative rate during the forecast period owing to its rising incidence coupled with advanced therapies such as rituximab and chemotherapy available for treating this condition. Marginal zone lymphoma also has an extensive treatment window which includes both chemo-immunotherapy along with biologics like rituximab, vedolizumab, etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, a favorable reimbursement scenario, and increasing healthcare expenditure are some of the major factors contributing to its growth. In addition, approval for new indications and rising awareness levels among patients are expected to drive regional demand over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China & India and supportive government initiatives aimed at generating revenue from novel drugs. Moreover, growing R&D activities by companies for drug development is also expected to contribute toward regional growth over the next eight years ( 2030). For instance, Sun Pharma’s collaboration with Pfizer Inc., for developing generic version of Imbruvica was approved by China FDA in June 2018; this will reduce costs associated with development process thus making it affordable for wider population base (Sun Pharmaceutical Industries Ltd vf Pfizer Inc.).
Growth Factors:
- Increasing incidence of chronic lymphocytic leukemia (CLL) and other B-cell malignancies: The global Imbruvica market is expected to grow at a CAGR of over 9% from 2016 to 2024, owing to the increasing incidence of chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
- Growing demand for novel therapies: There is a growing demand for novel therapies, such as Imbruvica, due to the high unmet needs in the oncology segment. This is expected to drive the growth of the global Imbruvica market during the forecast period.
- Rising awareness about available treatment options: The rising awareness about available treatment options is another key factor that is expected to drive growth in this market during the forecast period.
- Technological advancements: The advent of new technologies has led to significant improvements in cancer treatments, such as targeted therapy and immunotherapy, which are likely to boost adoption rates for Imbruvica and fuel its growth in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Imbruvica Market Research Report
By Type
5 mg, 10 mg, 140 mg
By Application
Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma, Chronic Graft-Versus-Host-Disease
By Companies
AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech), SP Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Imbruvica Market Report Segments:
The global Imbruvica market is segmented on the basis of:
Types
5 mg, 10 mg, 140 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma, Chronic Graft-Versus-Host-Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie (Pharmacyclics)
- Johnson & Johnson (Janssen Biotech)
- SP Laboratories
Highlights of The Imbruvica Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg
- 10 mg
- 140 mg
- By Application:
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenström's Macroglobulinemia
- Relapsed/Refractory Marginal Zone Lymphoma
- Chronic Graft-Versus-Host-Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Imbruvica Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Imbruvica is a medication used to treat chronic lymphocytic leukemia (CLL). It works by stopping the growth of cancer cells.
Some of the major companies in the imbruvica market are AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech), SP Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Imbruvica Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Imbruvica Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Imbruvica Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Imbruvica Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Imbruvica Market Size & Forecast, 2018-2028
4.5.1 Imbruvica Market Size and Y-o-Y Growth
4.5.2 Imbruvica Market Absolute $ Opportunity
Chapter 5 Global Imbruvica Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Imbruvica Market Size Forecast by Type
5.2.1 5 mg
5.2.2 10 mg
5.2.3 140 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Imbruvica Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Imbruvica Market Size Forecast by Applications
6.2.1 Mantle Cell Lymphoma
6.2.2 Chronic Lymphocytic Leukemia
6.2.3 Waldenström's Macroglobulinemia
6.2.4 Relapsed/Refractory Marginal Zone Lymphoma
6.2.5 Chronic Graft-Versus-Host-Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Imbruvica Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Imbruvica Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Imbruvica Analysis and Forecast
9.1 Introduction
9.2 North America Imbruvica Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Imbruvica Market Size Forecast by Type
9.6.1 5 mg
9.6.2 10 mg
9.6.3 140 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Imbruvica Market Size Forecast by Applications
9.10.1 Mantle Cell Lymphoma
9.10.2 Chronic Lymphocytic Leukemia
9.10.3 Waldenström's Macroglobulinemia
9.10.4 Relapsed/Refractory Marginal Zone Lymphoma
9.10.5 Chronic Graft-Versus-Host-Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Imbruvica Analysis and Forecast
10.1 Introduction
10.2 Europe Imbruvica Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Imbruvica Market Size Forecast by Type
10.6.1 5 mg
10.6.2 10 mg
10.6.3 140 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Imbruvica Market Size Forecast by Applications
10.10.1 Mantle Cell Lymphoma
10.10.2 Chronic Lymphocytic Leukemia
10.10.3 Waldenström's Macroglobulinemia
10.10.4 Relapsed/Refractory Marginal Zone Lymphoma
10.10.5 Chronic Graft-Versus-Host-Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Imbruvica Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Imbruvica Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Imbruvica Market Size Forecast by Type
11.6.1 5 mg
11.6.2 10 mg
11.6.3 140 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Imbruvica Market Size Forecast by Applications
11.10.1 Mantle Cell Lymphoma
11.10.2 Chronic Lymphocytic Leukemia
11.10.3 Waldenström's Macroglobulinemia
11.10.4 Relapsed/Refractory Marginal Zone Lymphoma
11.10.5 Chronic Graft-Versus-Host-Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Imbruvica Analysis and Forecast
12.1 Introduction
12.2 Latin America Imbruvica Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Imbruvica Market Size Forecast by Type
12.6.1 5 mg
12.6.2 10 mg
12.6.3 140 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Imbruvica Market Size Forecast by Applications
12.10.1 Mantle Cell Lymphoma
12.10.2 Chronic Lymphocytic Leukemia
12.10.3 Waldenström's Macroglobulinemia
12.10.4 Relapsed/Refractory Marginal Zone Lymphoma
12.10.5 Chronic Graft-Versus-Host-Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Imbruvica Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Imbruvica Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Imbruvica Market Size Forecast by Type
13.6.1 5 mg
13.6.2 10 mg
13.6.3 140 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Imbruvica Market Size Forecast by Applications
13.10.1 Mantle Cell Lymphoma
13.10.2 Chronic Lymphocytic Leukemia
13.10.3 Waldenström's Macroglobulinemia
13.10.4 Relapsed/Refractory Marginal Zone Lymphoma
13.10.5 Chronic Graft-Versus-Host-Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Imbruvica Market: Competitive Dashboard
14.2 Global Imbruvica Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie (Pharmacyclics)
14.3.2 Johnson & Johnson (Janssen Biotech)
14.3.3 SP Laboratories
